The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
Oct 20, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Tarshay Boyd, PharmD. Candidate, LECOM School of Pharmacy
This article is part of a live interview about VERTIS CV with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Cardiovascular events and renal disease in type 2 diabetes are an area of focus seen in studies across the world, including studies of heart failure, stroke, myocardial infarction, and renal disease progression.
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors play a critical role in managing type 2 diabetes and its complications. The purpose of the VERTIS CV study was to evaluate the cardiovascular effects of ertugliflozin, an SGLT-2 inhibitor. Other studies have assessed SGLT-2 inhibitors' effects on cardiovascular and kidney outcomes, showing significant hospitalization benefits for heart failure and renal disease progression. DAPA-CKD showed that dapagliflozin reduced the risk of kidney disease progression and death in patients with chronic kidney disease with or without type 2 diabetes....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.